Ceresnak Scott R, Nappo Lynn, Janson Christopher M, Pass Robert H
Pediatric Electrophysiology, Department of Pediatrics, Pediatric Cardiology, Lucile Packard Children's Hospital, Stanford University, Palo Alto, California.
Department of Pediatrics, Division of Pediatric Cardiology, Pediatric Arrhythmia Service, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, New York.
Pacing Clin Electrophysiol. 2016 Jan;39(1):36-41. doi: 10.1111/pace.12754. Epub 2015 Oct 30.
CARTO3 is frequently used during ablation but is not designed to allow visualization of non-CARTO3 ablation catheters. We describe how cryoablation catheters can be visualized and recorded using CARTO3 with minimal fluoroscopy (FLUORO) usage.
Retrospective review of patients ≤21 years undergoing cryoablation with CARTO3 from 2010 to 2013 for ablation of supraventricular tachycardia. After mapping with a Navistar catheter, the Navistar was removed and a cryocatheter was utilized. The cryocatheter was connected to the pin box via a jumper cable and the pin box was connected to the CARTO3 patient interface unit. Locations of ablation attempts with the cryocatheter were recorded with the "Create Snapshot" tool. Clinical characteristics and radiation doses were compared between patients undergoing cryoablation (cryoenergy [CRYO]) to an age- and diagnosis-matched control group (CONTROL) undergoing RF ablation.
A total of 174 ablations were performed and 14 patients underwent cryoablation (CRYO, 13.3 ± 4.7 years, weight 42 ± 14 kg). Indications for cryoablation were: five atrioventricular nodal reentry tachycardia (36%), four ectopic atrial tachycardia (29%), three concealed accessory pathways (21%), and two Wolff-Parkinson-White syndromes (14%). Acute success was achieved in all patients (100%) with no complications and one recurrence (7%). The site of successful cryoablation was successfully recorded on the CARTO3 system in all cases. Radiation doses were low and not different from an age-, era-, and diagnosis-matched control group undergoing RF ablation (CRYO 3.2 ± 0.8 mGy vs CONTROL 1.6 ± 0.4 mGy, P = 0.07).
Though a "closed" system, CARTO3 can be "tricked" to allow for the use of cryoablation, allowing clear catheter visualization, mapping, and recording of ablation lesions with minimal FLUORO usage.
CARTO3在消融过程中经常使用,但它并非设计用于可视化非CARTO3消融导管。我们描述了如何使用CARTO3以最少的透视(FLUORO)使用量来可视化和记录冷冻消融导管。
回顾性分析2010年至2013年间接受CARTO3冷冻消融治疗室上性心动过速的≤21岁患者。使用Navistar导管进行标测后,移除Navistar导管并使用冷冻导管。冷冻导管通过跨接电缆连接到针盒,针盒连接到CARTO3患者接口单元。使用“创建快照”工具记录冷冻导管消融尝试的位置。将接受冷冻消融(冷冻能量[CRYO])的患者与年龄和诊断匹配的接受射频消融的对照组(CONTROL)的临床特征和辐射剂量进行比较。
共进行了174次消融,14例患者接受了冷冻消融(CRYO组,年龄13.3±4.7岁,体重42±14kg)。冷冻消融的适应证为:5例房室结折返性心动过速(36%),4例房性异位性心动过速(29%),3例隐匿性旁路(21%),2例预激综合征(14%)。所有患者均获得急性成功(100%),无并发症,1例复发(7%)。所有病例中,冷冻消融成功部位均成功记录在CARTO3系统上。辐射剂量较低,与年龄、时代和诊断匹配的接受射频消融的对照组无差异(CRYO组3.2±0.8mGy vs CONTROL组1.6±0.4mGy,P=0.07)。
尽管CARTO3是一个“封闭”系统,但可以“欺骗”它以允许使用冷冻消融,从而在最少的透视使用量下实现清晰的导管可视化、标测和消融灶记录。